Skip to content
AnalystLens

CoreWeave 8-K Report, Regulation FD Disclosure (Jul 21, 2025)

Reports
Regulation FD·Exhibits & Filings
Filing Date
Filed July 21, 2025
Period End
July 21, 2025
Security
CRWV
In the record · 2025–202610-K110-Q58-K38

CRWV filed 1 annual reports (10-K), 5 quarterly reports (10-Q) and 38 current reports (8-K) between 2025 and 2026.

  1. Material agreement8-K · Jan ’26Jan ’26
  2. Material agreement8-K · Sep ’26Sep ’26

01—Abstract

Summary

Summary of the 8-K filed July 21, 2025. Cited figures are marked; the original filing is the authoritative source.

On July 21, 2025, CoreWeave (Nasdaq: CRWV) announced its intention to offer $1,500 milliona of senior unsecured notes due 2031 in a private offering to qualified institutional buyers under Rule 144A and non-U.S. persons under Regulation S.

The notes will be guaranteed on a senior unsecured basis by certain wholly-owned subsidiaries. The company states the proceeds will go to general corporate purposes, including repayment of outstanding indebtedness, and to pay offering fees and expenses. The filing is a Regulation FD disclosure, so no financial statements were filed with it; the offering terms (pricing, coupon, final size) were not yet set.

The supplemental investor materials (Exhibit 99.2) show the financing is primarily a refinancing and balance-sheet expansion. As of March 31, 2025, CoreWeave had $1,276 millionb of cash and $8,559 million of total debt. Pro forma for recent transactions (including the $2,000 million 9.250% Senior Notes due 2030, the repayment of the $1,000 million 2024 Term Loan, and DDTL-2 borrowings), total debt would be about $10,722 million.

Adding the new notes in full would bring pro forma total debt to roughly $11,772 millionc and cash to about $4,701 million, with the company citing $1,721 million of 1Q'25 LTM Adjusted EBITDA against a $1,049 million LTM net loss. Investors should weigh the growth-financing context against leverage and profitability.

The materials project net debt of about $17.3 billiond (3.0x run-rate Adjusted EBITDA of $5.8 billion), and that projection depends on $4.1 billion of anticipated run-rate contract profits and synergies from the pending Core Scientific acquisition, which may not close. Debt is rising quickly, and the company reported a GAAP net loss over the trailing twelve months, so the outcome of the offering and the realization of those projected figures will matter for credit and equity holders.

02—Key points

Key Highlights

  1. Proposed $1,500 million senior unsecured notes due 2031, guaranteed by certain wholly-owned subsidiaries, offered under Rule 144A and Regulation S; terms and pricing not yet disclosed.
  2. Proceeds earmarked for general corporate purposes, including repaying existing indebtedness, and paying offering fees and expenses.
  3. As of 3/31/25, CoreWeave had $1,276 million cash and $8,559 million total debt; pro forma total debt would reach about $11.8 billion after this offering.
  4. 1Q'25 LTM Adjusted EBITDA of $1,721 million versus an LTM GAAP net loss of $1,049 million, with Adjusted EBITDA excluding large D&A ($1,227 million) and interest expense ($584 million).
  5. Projected total net debt of $17.3 billion (3.0x run-rate Adj. EBITDA of $5.8 billion) relies on $4.1 billion of projected run-rate contract profits and Core Scientific acquisition synergies that are not assured.
  6. Rapid infrastructure growth: active power rose from about 10 MW (Dec-22) to about 420 MW (Mar-25) across 33 data centers.
  7. Filing is a Regulation FD disclosure with Exhibits 99.1 (press release) and 99.2 (investor supplement); the furnished information is not deemed filed under Section 18 of the Exchange Act.

03—Questions

Frequently Asked Questions

  1. How much is CoreWeave raising, and what is the debt's maturity?

    CoreWeave intends to offer $1,500 million aggregate principal amount of senior notes due 2031. The offering is subject to market and customary conditions, and final pricing and terms were not disclosed in this filing.

  2. What will the proceeds be used for?

    The company plans to use the proceeds for general corporate purposes, including repaying outstanding indebtedness and paying fees and expenses related to the offering. The supplemental materials show the notes would be used to reduce the revolving credit facility balance by $450 million on an illustrative basis.

  3. How does this offering change CoreWeave's leverage?

    Based on the supplemental data, total debt would rise from about $10.7 billion (pro forma for recent transactions) to about $11.8 billion, and cash would increase to about $4.7 billion. Projected net debt of $17.3 billion equals about 3.0x run-rate Adjusted EBITDA, but that projection includes forward-looking assumptions and $8.8 billion of projected secured debt to service contracts.

  4. Is CoreWeave profitable?

    Not on a GAAP basis. The LTM net loss through 1Q'25 was $1,049 million. Adjusted EBITDA, a non-GAAP measure, was $1,721 million over the same period, but it excludes depreciation, interest, stock-based compensation, and fair value adjustments, so it is not a substitute for GAAP results.

  5. What risks should investors consider?

    Key risks include whether the offering completes on favorable terms, the realization of projected run-rate profits and Core Scientific acquisition synergies (which may not close), rising debt levels and interest costs, and dependence on large AI contracts and data center capacity growth.

04—Continue

← View all 8-K filings